Knobias Clip Report (07-18-2008) MDVN
Submitted By Knobias ClipReport
MDVN: Publication of Positive Data re Dimebon Published in Lancet
By Fain Hughes, fhughes@knobias.com
Medivation, Inc. (MDVN) announced the publication of the results of its first Alzheimer’s disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet. In this double-blind, placebo-controlled trial, patients with mild-to-moderate Alzheimer’s disease treated with Dimebon experienced statistically significant improvements compared to placebo in all the key aspects of the disease: memory and thinking, activities of daily living, behavior and overall function.
After both six months and a full year of treatment, Dimebon-treated patients were significantly better than placebo-treated patients on all key aspects of the disease. The benefit on the primary endpoint, the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) at six months, was highly significant (p<0.0001). Patients treated with Dimebon were also significantly improved at six months over baseline on all measures (p=0.005 on ADAS-cog). Dimebon's benefit over placebo continued to increase throughout the 12-month treatment period.
Visit 1800blogger to see all of our industry leading blogs.
